Get the app
Help
Download the app
Anghami Plus
Browse content
Moods and genres
Podcasts
OSN Plus
The Lancet Respiratory Medicine in conversation with
by The Lancet Group
160 EPISODES
Apr 2022
Play for free
All Episodes
Laura Garriga-Grimau on bronchiectasis in children and young people
The Lancet Group
Marcus J Schultz and Prashant Nasa on defining and subphenotyping ARDS
The Lancet Group
Hjalmar Bouma on sepsis in patients who are immunocompromised
The Lancet Group
Simon Wolf on pulmonary embolism in children and adolescents in the US during 2016 and 2019
The Lancet Group
Sandeep Sahay and Franck Rahaghi on future treatment paradigms in pulmonary arterial hypertension
The Lancet Group
Sergio Harari sul trattamento della linfangioleiomiomatosi (LAM) (in Italian)
The Lancet Group
Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)
The Lancet Group
Robert Kullberg on empirical antibiotics for Sepsis
The Lancet Group
Heather Zar on early-life RSV disease and long-term respiratory health
The Lancet Group
Margaux Mesle on lives saved by COVID-19 vaccination
The Lancet Group
James Hull on protecting the respiratory health of athletes
The Lancet Group
Eric Lim on treatments for pleural mesothelioma
The Lancet Group
Anne Chang on the burden of chronic respiratory diseases in Indigenous people
The Lancet Group
Daniel Steinfort and Shankar Siva on radiotherapy field planning in patients with NSCLC
The Lancet Group
Daniel Prieto-Alhambra, Annika Jödicke, and Martí Català on vaccination to prevent Long COVID
The Lancet Group
Sarah Gorst and Tim Nicholson on long COVID outcomes
The Lancet Group
Betty Raman on multiorgan MRI abnormalities after hospitalisation with COVID-19
The Lancet Group
Keith Chappell on a bivalent recombinant vaccine for COVID-19
The Lancet Group
James Chalmers on bronchiectasis across Europe
The Lancet Group
Richard Costello on management of uncontrolled asthma
The Lancet Group
Keiju Aokage on segmentectomy for ground-glass-dominant lung cancer
The Lancet Group
Carol Hodgson on post-discharge outcomes for ECMO patients
The Lancet Group
Emma Grainger on 10 years of The Lancet Respiratory Medicine
The Lancet Group
Vivienne Kahlmann and Catharina Moor on the TIRED study
The Lancet Group
Yves Lacasse on long-term oxygen therapy for COPD
The Lancet Group
Rachael Evans on living with long COVID
The Lancet Group
Daniel Munblit and Dale Needham on core outcomes post-COVID-19
The Lancet Group
Daiana Stolz on antibiotic stewardship in pneumonia
The Lancet Group
Ablo Wachinou on sleep disordered breathing in Benin
The Lancet Group
Peter Openshaw and Felicity Liew on corticosteroids in the early in the treatment of COVID
The Lancet Group
Dinh Bui on preterm birth and lung function deficits
The Lancet Group
Ruvim Izĭckson on a joint flu and COVID-19 vaccine
The Lancet Group
Wisia Wedzicha on a vaccine for COPD
The Lancet Group
Eileen Rubin on patient-centered ARDS
The Lancet Group
Daniel Altmann on COVID boosters
The Lancet Group
Michael Kreuter on interstitial lung disease
The Lancet Group
Bairbre McNicholas and Jie Li on awake prone positioning and COVID-19
The Lancet Group
Charles Sprung and authors on end-of-life practices in ICUs globally
The Lancet Group
Christopher Brightling on tezepelumab in patients with moderate-to-severe uncontrolled asthma
The Lancet Group
Paul Verweij on COVID-19 associated aspergillosis
The Lancet Group
Ignacio Rubio on COVID-19 pathophysiology and phenotypes
The Lancet Group
Kiran Shekar on cytokine adsorption and severe COVID-19 pneumonia
The Lancet Group
Fan Chung on chronic cough and long COVID
The Lancet Group
Mepolizumab and the treatment of chronic rhinosinusitis
The Lancet Group
Inhaled budesonide in the treatment of early COVID-19
The Lancet Group
Tocilizumab and COVID-19
The Lancet Group
Interferon treatment and COVID-19
The Lancet Group
Evaluating deterioration in patients with acute COVID-19
The Lancet Group
Treatment options in patients with systemic sclerosis-associated interstitial lung disease
The Lancet Group
COVID-19 and severe influenza
The Lancet Group